Literature DB >> 8513449

Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.

J Kan-Mitchell1, X Q Huang, L Steinman, J R Oksenberg, W Harel, J W Parker, P S Goedegebuure, T L Darrow, M S Mitchell.   

Abstract

To study in vivo activated cytolytic T cells, CD8+ T cells clones were isolated from a melanoma patient (HLA A2, A11) treated with active specific immunotherapy for 5 years. CD8+ T lymphocytes, purified by fluorescence-activated cell sorting, were cloned directly from the peripheral blood without antigen-presenting cells in the presence of irradiated autologous melanoma cells and recombinant interleukin-2 (IL-2) and IL-4. These conditions were inhibitory to de novo in vitro immunization. Of the 28 cytolytic CD8+ T cell clones, 21 lysed the autologous melanoma cell line (M7) but not the autologous lymphoblastoid cell line (LCL-7) nor the two melanoma cell line, M1 (HLA A28) and M2 (HLA A28, A31), used to immunize the patient. The remaining 7 clones were also melanoma-specific, although their reactivities were broader, lysing several melanoma cell lines but not HLA-matched lymphoblastoid cells. Eight clones from the first group, ostensibly self-MHC-restricted, were expanded for further analysis. All expressed cluster determinants characteristic of mature, activated T cells, but not those of thymocytes, naive T cells, B cells or natural killer (NK) cells. They also expressed CD13, a myeloid marker. Of the 8 clones, 3 expressed both CD4 and CD8, but dual expression was not correlated with specificity of lysis. Two CD8+ and 2 CD4+ CD8+ clones were specific for the autologous melanoma cells, the other 4 were also reactive against other HLA-A2-positive melanomas. Cytotoxicity for both singly and doubly positive clones was restricted by HLA class I but not class II antigens. Analysis of the RNA expression of the T cell receptor (TCR) V alpha and V beta gene segments revealed heterogeneous usage by the A2-restricted clones and, perhaps, also by the broadly melanoma-specific clones. Apparent TCR-restricted usage was noted for the self-MHC-restricted clones; 2 of the 4 expressed the V alpha 17/V beta 7 dimer. Since the T cell clones were derived from separate precursors of circulating cytotoxic T lymphocytes (CTL), the V alpha 17/V beta 7 TCR was well represented in the peripheral blood lymphocytes of this patient. In summary, we show that melanoma cells presented their own antigens to stimulate the proliferation of melanoma-reactive CD8+ CTL. CTL with a range of melanoma specificities and different TCR alpha beta dimers were encountered in this patient, perhaps as a result of hyperimmunization.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8513449     DOI: 10.1007/BF01516937

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  53 in total

1.  Predominant T cell receptor gene elements in TNP-specific cytotoxic T cells.

Authors:  B Kempkes; E Palmer; S Martin; A von Bonin; K Eichmann; B Ortmann; H U Weltzien
Journal:  J Immunol       Date:  1991-10-15       Impact factor: 5.422

Review 2.  Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?

Authors:  G Parmiani; A Anichini; G Fossati
Journal:  J Natl Cancer Inst       Date:  1990-03-07       Impact factor: 13.506

3.  Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans.

Authors:  B M Vose; F Vanky; E Klein
Journal:  Int J Cancer       Date:  1977-10-15       Impact factor: 7.396

4.  The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells.

Authors:  S R Riddell; P D Greenberg
Journal:  J Immunol Methods       Date:  1990-04-17       Impact factor: 2.303

5.  Active-specific immunotherapy for melanoma.

Authors:  M S Mitchell; W Harel; R A Kempf; E Hu; J Kan-Mitchell; W D Boswell; G Dean; L Stevenson
Journal:  J Clin Oncol       Date:  1990-05       Impact factor: 44.544

6.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

7.  Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia.

Authors:  R E Sobol; R Mick; I Royston; F R Davey; R R Ellison; R Newman; J Cuttner; J D Griffin; H Collins; D A Nelson
Journal:  N Engl J Med       Date:  1987-04-30       Impact factor: 91.245

8.  Presence on a human melanoma of multiple antigens recognized by autologous CTL.

Authors:  B Van den Eynde; P Hainaut; M Hérin; A Knuth; C Lemoine; P Weynants; P van der Bruggen; R Fauchet; T Boon
Journal:  Int J Cancer       Date:  1989-10-15       Impact factor: 7.396

9.  IL-4 regulates IL-2 induction of lymphokine-activated killer activity from human lymphocytes.

Authors:  Y Kawakami; M C Custer; S A Rosenberg; M T Lotze
Journal:  J Immunol       Date:  1989-05-15       Impact factor: 5.422

10.  T cell receptor V beta gene usage in a human alloreactive response. Shared structural features among HLA-B27-specific T cell clones.

Authors:  R Bragado; P Lauzurica; D López; J A López de Castro
Journal:  J Exp Med       Date:  1990-04-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Relevance of the T cell receptor for immunotherapy of cancer.

Authors:  E Weidmann; M Trucco; T L Whiteside
Journal:  Cancer Immunol Immunother       Date:  1994-07       Impact factor: 6.968

2.  Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients.

Authors:  X Q Huang; M S Mitchell; P E Liggett; A L Murphree; J Kan-Mitchell
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

3.  Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.

Authors:  L G LeMay; J Kan-Mitchell; P Goedegebuure; W Harel; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

4.  Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.

Authors:  Richard T Williams; Lisa M Barnhill; Huan-Hsien Kuo; Wen-Der Lin; Ayse Batova; Alice L Yu; Mitchell B Diccianni
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

5.  Cytotoxic activity of CD4+ T cells against autologous tumor cells.

Authors:  Y Konomi; T Sekine; T Takayama; M Fuji; T Tanaka
Journal:  Jpn J Cancer Res       Date:  1995-09

6.  Expression of aminopeptidase N/CD13 in tumour-infiltrating lymphocytes from human renal cell carcinoma.

Authors:  D Riemann; B Göhring; J Langner
Journal:  Immunol Lett       Date:  1994-09       Impact factor: 3.685

7.  Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope.

Authors:  Keri L Schaubert; David A Price; Nicole Frahm; Jinzhu Li; Hwee L Ng; Aviva Joseph; Elyse Paul; Biswanath Majumder; Velpandi Ayyavoo; Emma Gostick; Sharon Adams; Francesco M Marincola; Andrew K Sewell; Marcus Altfeld; Jason M Brenchley; Daniel C Douek; Otto O Yang; Christian Brander; Harris Goldstein; June Kan-Mitchell
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.